# Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)

> **NCT04647903** · PHASE1 · COMPLETED · sponsor: **Vallon Pharmaceuticals, Inc.** · enrollment: 55 (actual)

## Conditions studied

- ADHD
- Narcolepsy

## Interventions

- **DRUG:** ADAIR 10 mg IR tablets
- **DRUG:** d-amphetamine sulfate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04647903
- **Lead sponsor:** Vallon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-05
- **Primary completion:** 2021-12-17
- **Final completion:** 2021-12-17
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2021-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04647903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04647903, "Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04647903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*